Compare XBIT & MPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XBIT | MPV |
|---|---|---|
| Founded | 2005 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.8M | 169.4M |
| IPO Year | 2015 | N/A |
| Metric | XBIT | MPV |
|---|---|---|
| Price | $1.88 | $16.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 92.8K | 9.0K |
| Earning Date | 11-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.71% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.71 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $30.47 | N/A |
| P/E Ratio | ★ N/A | $9.58 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.80 | $15.05 |
| 52 Week High | $3.44 | $20.24 |
| Indicator | XBIT | MPV |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 47.37 |
| Support Level | $1.80 | $16.05 |
| Resistance Level | $2.42 | $17.33 |
| Average True Range (ATR) | 0.12 | 0.40 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 27.27 | 44.21 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.